Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Open-market sale Director sold 38,353 shares at an average $59.72 ($2,290,536)
  2. 4 Option exercise Chief Scientific Officer acquired 9,996 shares (option exercise)
  3. 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $64.56 ($64,556)
  4. 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $64.48 ($341,750)
  5. 4 Open-market sale Director sold 23,959 shares at an average $56.45 ($1,352,499)
  6. 4 Open-market sale Director sold 23,690 shares at an average $61.13 ($1,448,078)
  7. 4 Option exercise Chief Scientific Officer acquired 33,200 shares (option exercise)
  8. 4 Open-market sale Director sold 28,617 shares at an average $60.87 ($1,742,043)
  9. 4 Open-market sale Director sold 19,029 shares at an average $63.53 ($1,208,936)
  10. 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $64.84 ($64,841)
  11. 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $64.91 ($344,017)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 3 Insider Initial Statement of Ownership
  18. 4 Open-market buy Director bought 60,000 shares at $50.00 ($3,000,000)
  19. 4 Open-market buy Director bought 60,000 shares at $50.00 ($3,000,000)
  20. 4 Open-market buy 10% owner bought 60,000 shares at $50.00 ($3,000,000)

Page 9 of 11 · 207 filings